NAS:CNCR

Range Cancer Therapeutics ETF

$ 14.39 0.44 ( +3.15%) 03:26 PM EST
PE Ratio:
20.85
PB Ratio:
2.06
Volume:
3.23K
Dividend Yield %:
0
Last Holding update 2024-02-01 86 Stocks (0 new)
Value $11.00 Mil Turnover 28 %
Top Holdings: IBRX(2.50%) RVMD(2.30%) IMGN(2.28%) MGNX(2.15%) MRTX(2.10%)
Portfolio Report
Registrant: Range Cancer Therapeutics ETF
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Performance Chart Fundamental Charts Technical Indicators Gurus Trades Top Holdings Sector Breakdowns Holding History Back to Top

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Key Statistics

Name Value
Day's Open ($) 13.9658
Day's Range ($) 13.94 - 14.4302
Day's Volume 3,231
52-Week Range ($) 9.22 - 17.96
Beta 0.82
Volatility 39.19
14-Day RSI 33.56
14-Day ATR ($) 0.457691
20-Day SMA ($) 15.2005

Fundamental Data

Name Value
Market Cap (Mil $) 17.711
Shares Outstanding (Mil) -
PE Ratio 20.85
PE Ratio (10y Range) 12.64 - 20.85
PE Ratio (10y Median) 20.85
PB Ratio 2.06
PB Ratio (10y Range) 2.06 - 5.84
PB Ratio (10y Median) 4.38

Dividend Data

Name Value
Dividends per Share (TTM) ($) -
Dividend Yield % -
Dividend Yield % (10y Range) 0.4 - 14.16
Dividend Yield % (10y Median) 1.31
Next Dividend Payment Date
Dividend Frequency -

CNCR Range Cancer Therapeutics ETF Fundamental Charts

Historical TTM Price-to-Earnings for CNCR Range Cancer Therapeutics ETF

Historical TTM Price-to-Earnings without NRI for CNCR Range Cancer Therapeutics ETF

Historical Price-to-Book Ratio for CNCR Range Cancer Therapeutics ETF

Historical Dividend Yields for CNCR Range Cancer Therapeutics ETF

CNCR Range Cancer Therapeutics ETF Technical Indicators

Moving Average

Momentum

Gurus Latest Trades with NAS:CNCR

No Available Data

NAS:CNCR is held by these investors

No Available Data
Range Cancer Therapeutics ETF's Top Stock Picks View Full List
Ticker
Ticker
Company
Date
Action
Impact %
Price Range
Price
Price Change from Avrg%
Comment
Current Shares
Share Change

Range Cancer Therapeutics ETF Total Holding History ($B)

To

Range Cancer Therapeutics ETF's Asset Allocation

To

Range Cancer Therapeutics ETF Past Portfolios

Portfolio Date Number of Stocks New Stocks Total Value ($Mil) Q/Q Turnover

Top Ranked Articles

  • 1

Range Cancer Therapeutics ETF's Hypothetical Growth since 2023-11-30

Range Cancer Therapeutics ETF's Yearly Returns

Year Portfolio % % Excess Gain %

Range Cancer Therapeutics ETF's Holdings Heat Map

Size field:

Range Cancer Therapeutics ETF's Holdings Bubble Chart

Range Cancer Therapeutics ETF News

  • 1

Discussions on Range Cancer Therapeutics ETF

How would you rate this stock? CNCR
No discussions yet.
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.